Company Overview
Company Name
Aerogen Pharma
Website
aerogenpharma.comPhone
+353 91 540 400Approx. Annual Revenue
$7.2M
Employees
40
Established
2015
About Aerogen Pharma
Aerogen Pharma is an Irish specialty pharmaceutical company developing the first generation of inhaled drugs for acute and critical care settings. Leveraging industry-leading expertise and a proven track record in inhalation therapeutics, Aerogen Pharma is creating a new standard for aerosol drug delivery to the lungs through its patented technology platform.
Business Profile
Read from the Aerogen Pharma website on Oct 13, 2026. Hover an item to see the exact wording it came from.
About the website
- Website quality (AI-assessed)
- 7/10 · Clear company and technology info; Contact form present
- Footer copyright year
- 2023
Frequently Asked Questions about Aerogen Pharma
Categories
Technologies Used
%20--%3e%3csvg%20version='1.1'%20id='st_x5F_cc_x5F_app_x5F_RGB.svg'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20240.0004%20234.0004'%20style='enable-background:new%200%200%20240.0004%20234.0004;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:url(%23SVGID_1_);}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3clinearGradient%20id='SVGID_1_'%20gradientUnits='userSpaceOnUse'%20x1='119.9997'%20y1='234.0002'%20x2='119.9997'%20y2='0.0002'%3e%3cstop%20offset='0'%20style='stop-color:%23201F21'/%3e%3cstop%20offset='1'%20style='stop-color:%23313131'/%3e%3c/linearGradient%3e%3crect%20x='-0.0003'%20y='0.0002'%20class='st0'%20width='240'%20height='234'/%3e%3cg%3e%3cpath%20class='st1'%20d='M132.24969,97.95853c-5.60328,18.77988-10.28088,36.91208-15.88416,54.63138%20c-3.18081,9.99579-6.66385,19.53729-11.05544,25.59485c-4.84678,6.81497-13.93402,13.32771-24.83743,13.32771%20c-7.72443,0-15.29683-3.63509-15.29683-11.66174c0-4.99789,5.14901-9.69264,9.23837-9.69264%20c2.42339,0,3.63508,1.36282,4.24046,2.42339c3.7862,6.81497,7.42128,10.75229,9.08724,10.75229s3.02878-2.27135,5.7544-12.1151%20l19.82331-73.26013H99.08337c-1.06058-3.18081,0.45427-7.11812,2.27135-7.87554h14.23625%20c2.72562-8.7841,5.92356-17.60862,10.46719-25.63529c6.81497-12.26713,17.7193-21.95976,32.71205-21.95976%20c11.3586,0,16.05333,5.45216,16.05333,12.41917c-0.15111,7.42036-6.66293,11.20656-9.69263,11.20656%20c-2.42247,0-3.63416-1.81709-4.39159-4.39159c-2.57451-9.69263-5.90643-12.57029-7.87555-12.57029%20c-1.9682,0-4.99789,3.63416-8.3289,11.20656c-4.3925,9.54151-7.28729,19.72977-10.01291,29.72464h17.26501%20c1.05966,2.12023,0.15112,6.66385-2.42339,7.87554H132.24969z'/%3e%3c/g%3e%3c/svg%3e)
Key Decision Makers
David Durand Chief Medical Officer
Tim Warneke Vice President Clinical Operations
Antoinette Santoro Clinical Trial Manager
Jim Fink Chief Scientific Officer
Vidya Joshi Chief Development Officer
Brian Noga Chief Executive Officer
Carmen Jacome Director of Program Management
Monika Thielen Clinical Trial Manager
Hee-Byung Choe Associate Clinical Trial Manager